Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,058,552

« Back to Dashboard

Summary for Patent: 4,058,552

Title: Esters of p-carbonylphenoxy-isobutyric acids
Abstract:This invention is concerned with esters of p-carbonylphenoxy-isobutyric acids of the general formulae: ##STR1## WHEREIN R is a phenyl group substituted by one or two halogen atoms; R' is H, CH.sub.3, C.sub.6 H.sub.5, SCH.sub.3, OCH.sub.3, or, SO.sub.2 CH.sub.3 ; R" is CH.sub.3 or C.sub.2 H.sub.5 ; Y is C.sub.1 -C.sub.4 alkoxy, phenoxy, phenoxy substituted by one or two halogen atoms, or, OCH.sub.2 O--CO--C(CH.sub.3).sub.3 ; Z is C.sub.1 -C.sub.4 alkyl, phenyl or R; Nr.sub.1 r.sub.2 is N(CH.sub.3).sub.2 N(C.sub.2 H.sub.5).sub.2, morpholino, piperidino, azepino, pyrrolidino. This invention is also concerned with acid addition salts obtained from formula Ia compounds with acids. Compounds of formulae I and Ia are useful as hypocholesterolemiant and hypolipidemiant agents.
Inventor(s): Mieville; Andre (Lausanne, CH)
Assignee: Orchimed SA (CH)
Application Number:05/600,127
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,058,552

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1517/69Jan 31, 1969
Switzerland13022/69Aug 28, 1969

International Patent Family for Patent: 4,058,552

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Belgium742484► Subscribe
Belgium790026► Subscribe
Brazil7016496► Subscribe
Canada960670► Subscribe
Switzerland515873► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus